RMP
SPRO icon

Richards, Merrill & Peterson’s Spero Therapeutics SPRO Stock Holding History

Richards, Merrill & Peterson’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-150
Closed -$155 – 524
2024
Q4 		$155 Buy
+150
New +$178 ﹤0.01% 496

Other funds holding SPRO

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Richards, Merrill & Peterson's SPRO Position: Q1 2025 in Review

Richards, Merrill & Peterson sold out of Spero Therapeutics (SPRO) in Q1 2025, closing a stake of 150 shares — an estimated $155 sold.

Richards, Merrill & Peterson first reported a position in SPRO in Q4 2024 and held it in 1 quarter. The position peaked at $155 in Q4 2024. 38 funds tracked by Wall St. Rank hold SPRO as of Q1 2025.

  • Richards, Merrill & Peterson reported no remaining Spero Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Richards, Merrill & Peterson sold 150 Spero Therapeutics shares in Q1 2025, an estimated $155.
  • Richards, Merrill & Peterson first reported a position in Spero Therapeutics in Q4 2024 and held it in 1 quarter.
  • Richards, Merrill & Peterson's Spero Therapeutics position peaked at $155 in Q4 2024.
  • 38 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2025.

Based on Richards, Merrill & Peterson's 13F filing for Q1 2025, filed 7 May 2025.